Pramlintide acetate - Generic Drug Details

What are the generic sources for pramlintide acetate and what is the scope of patent protection?

Pramlintide acetate is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for pramlintide acetate. One supplier is listed for this compound.

Summary for pramlintide acetate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	11
Clinical Trials:	21
What excipients (inactive ingredients) are in pramlintide acetate?	pramlintide acetate excipients list
DailyMed Link:	pramlintide acetate at DailyMed

Recent Clinical Trials for pramlintide acetate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Canadian Institutes of Health Research (CIHR)	N/A
Juvenile Diabetes Research Foundation	N/A
McGill University	N/A

See all pramlintide acetate clinical trials

Pharmacology for pramlintide acetate

Drug Class	Amylin Analog
Mechanism of Action	Amylin Agonists

Anatomical Therapeutic Chemical (ATC) Classes for pramlintide acetate

A10BX	Other blood glucose lowering drugs, excl. insulins
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

US Patents and Regulatory Information for pramlintide acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-002	Sep 25, 2007		DISCN	Yes	No
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-003	Sep 25, 2007		DISCN	Yes	No
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-001	Mar 16, 2005		DISCN	No	No

Expired US Patents for pramlintide acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-003	Sep 25, 2007
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-001	Mar 16, 2005
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-003	Sep 25, 2007
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-002	Sep 25, 2007
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-003	Sep 25, 2007
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-001	Mar 16, 2005

Market Dynamics and Financial Trajectory for Pramlintide Acetate

Last updated: February 14, 2026

Market Overview

Pramlintide acetate, marketed as Symlin in the United States, is a synthetic analog of human amylin used as an adjunct therapy for diabetes management, specifically for type 1 and type 2 diabetes. Approved by the FDA in 2005, it addresses postprandial glucose control by slowing gastric emptying and reducing glucagon secretion. Despite its clinical efficacy, its market penetration remains limited compared to earlier insulin therapies due to factors including administration route, patient acceptance, and market competition.

Market Size and Growth Drivers

The global diabetes medication market was estimated at USD 54.8 billion in 2021 and is projected to grow at a CAGR of approximately 7.5% through 2028. The segment incorporating injectable therapies like pramlintide contributes disproportionately to this growth due to unmet needs for optimal glycemic control and reduced side effects associated with other treatments.

Current Market Position of Pramlintide

In 2022, Pramlintide's annual sales revenue globally surpassed USD 200 million, primarily driven by its established use in the US. The drug holds a small share within the total diabetes market but retains growth potential tied to increasing diabetes prevalence, especially in developed countries. Competitive pressures from newer GLP-1 receptor agonists and SGLT2 inhibitors have impacted sales.

Competitive Landscape

The primary competitors include GLP-1 receptor agonists such as liraglutide (Victoza) and semaglutide (Ozempic), which offer less frequent dosing and easier administration. These agents achieved blockbuster status with sales exceeding USD 5 billion, diversifying the therapeutic options for diabetes patients and shifting market preferences away from injectable amylin analogs like pramlintide.

Regulatory and Patent Status

Pramlintide lacks recent patent extensions, with its original patent expiring around 2020. Absence of robust patent protection limits exclusivity and discourages significant marketing investment. However, the drug remains on the market due to existing manufacturing agreements and regulatory approvals.

Financial Outlook

Forecasts suggest that pramlintide's global sales will stabilize or decline modestly over the next five years, given the competitive environment. Adoption rates are expected to increase in specific niches, such as patients who cannot tolerate GLP-1 therapies or require additional postprandial glucose control.

Pricing Trends

Pricing varies from USD 150 to USD 250 per month per patient in the US. Insurance coverage influences patient access, with some payers favoring newer agents' cost-effectiveness. Price reduction pressures are anticipated as generics or biosimilars enter markets or as newer therapies dominate.

Investment and R&D Trends

Major pharmaceutical companies have limited ongoing investment in pramlintide development. Research focuses on combination therapies, including co-formulations with insulin, aiming to improve adherence and efficacy. Clinical trials exploring oral formulations or longer-acting analogs have had limited success to date.

Key Market Challenges

• Preference for alternative therapies: Easier-to-administer oral medications and less frequent injectable options dominate.
• Limited awareness and physician familiarity: Many practitioners prefer well-established treatments.
• Administrative burden: Multiple daily injections oppose patient adherence.

Opportunities

Emerging delivery technologies, such as implantable devices or oral formulations, could extend pramlintide's market relevance. Combining pramlintide with other therapies might optimize glycemic control and patient convenience.

Summary Table

Aspect	Data/Details
2022 global sales	USD 200 million
Market growth (2021–2028)	7.5% CAGR
Patent expiration	Around 2020
Pricing	USD 150 – USD 250/month per patient
Main competitors	GLP-1 receptor agonists (Victoza, Ozempic)
FDA approval date	2005

---

Key Takeaways

• Pramlintide acetate remains a niche medication with modest sales primarily in the US.
• Market growth is hindered by competition from newer, more convenient therapies.
• Patent expiration and lack of significant R&D investments limit its long-term expansion potential.
• Opportunities exist in combination formulation development and delivery innovations.

---

FAQs

1. What factors limit pramlintide’s market expansion?
Its administration requires multiple daily injections, and competition from oral agents and less frequent injectable therapies reduces its appeal. Limited physician familiarity and insurance reimbursement challenges further restrict uptake.

2. Are there new formulations or delivery methods under development for pramlintide?
Research explores co-formulations with insulin and alternative delivery systems like implantable devices. Oral formulations have been tested but face significant bioavailability challenges.

3. How does pricing compare with competing diabetes therapies?
Pramlintide costs approximately USD 150–USD 250 per month in the US, higher than some generic insulins and lower than branded GLP-1 receptor agonists, yet less price-competitive within the broader diabetes market.

4. What is the outlook for pramlintide’s sales over the next five years?
Sales are expected to remain stable or decline slightly as newer therapies gain dominance unless significant formulation or delivery advancements occur.

5. Is pramlintide likely to regain market share in the future?
Unlikely without innovation in administration or indication expansion, given current market preferences and existing therapeutic options.

---

Citations

1. MarketWatch. "Diabetes Drugs Market Size, Share & Trends Analysis." 2022.
2. EvaluatePharma. "Global Pharmaceutical Sales Data." 2023.
3. FDA. "Pramlintide Acetate (Symlin) Approval History." 2005.
4. Deloitte. "The Future of Diabetes Treatments." 2022.
5. IQVIA. "Pharmaceutical Market Trends." 2023.